Early pharmacological treatment of autism: a rationale for developmental treatment
- PMID: 17276749
- PMCID: PMC2553755
- DOI: 10.1016/j.biopsych.2006.09.021
Early pharmacological treatment of autism: a rationale for developmental treatment
Erratum in
- Biol Psychiatry. 2007 Mar 15;61(6):826
Abstract
Autism is a dynamic neurodevelopmental syndrome in which disabilities emerge during the first three postnatal years and continue to evolve with ongoing development. We briefly review research in autism describing subtle changes in molecules important in brain development and neurotransmission, in morphology of specific neurons, brain connections, and in brain size. We then provide a general schema of how these processes may interact with particular emphasis on neurotransmission. In this context, we present a rationale for utilizing pharmacologic treatments aimed at modifying key neurodevelopmental processes in young children with autism. Early treatment with selective serotonin reuptake inhibitors (SSRIs) is presented as a model for pharmacologic interventions because there is evidence in autistic children for reduced brain serotonin synthesis during periods of peak synaptogenesis; serotonin is known to enhance synapse refinement; and exploratory studies with these agents in autistic children exist. Additional hypothetical developmental interventions and relevant published clinical data are described. Finally, we discuss the importance of exploring early pharmacologic interventions within multiple experimental settings in order to develop effective treatments as quickly as possible while minimizing risks.
Figures


References
-
- Abramson R, Wright H, Carpenter R, Brennan W, Lumpuy O, Cole E, Young S. Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord. 1989;19:397–407. - PubMed
-
- Alcantara S, Pozas E, Ibanez CF, Soriano E. BDNF-modulated Spatial Organization of Cajal-Retzius and GABAergic Neurons in the Marginal Zone Plays a Role in the Development of Cortical Organization. Cereb Cortex. 2006;16:487–499. - PubMed
-
- Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003;33:93–7. - PubMed
-
- Aman MG. Treatment planning for patients with autism spectrum disorders. J Clin Psychiatry. 2005;66(Suppl 10):38–45. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources